THE European Medicines Agency (EMA) has confirmed patients treated with direct-acting retrovirals for hepatitis C such as Daklinza, Exviera, Harvoni, Solvadi, Olysio and Viekirax may be at risk of hepatitis B re-activation.
The EMA is recommending that before starting treatment all patients be screened for hep B.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 16